Compare YMT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | CRDF |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 142.1M |
| IPO Year | 2025 | N/A |
| Metric | YMT | CRDF |
|---|---|---|
| Price | $1.37 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 45.9K | ★ 868.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,547,440.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.68 | N/A |
| 52 Week Low | $1.00 | $1.90 |
| 52 Week High | $6.05 | $5.64 |
| Indicator | YMT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.72 |
| Support Level | N/A | $2.09 |
| Resistance Level | N/A | $2.49 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 83.33 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.